Diffuse Hemispheric Glioma H3 G34-mutant

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS withdrawal · 2025-02-24
Clinical Trial Update: Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant [Phase 1]
The Phase 1 trial of a peptide-pulsed dendritic cell vaccine in combination with nivolumab and ipilimumab for diffuse hemispheric glioma, H3…